PHOENIX

凤凰城

,

，

March 10, 2026

2026年3月10日

/PRNewswire/ --

/PRNewswire/ --

Trinity Capital Inc.

三一资本公司

(Nasdaq:

（纳斯达克：

TRIN

三因素指标

) (the 'Company'), a leading international alternative asset manager, today announced the commitment of $35 million in growth capital to Neuros Medical, Inc., a MedTech company focused on alleviating chronic post-amputation pain and restoring quality of life through neuromodulation technologies.

)（“公司”），一家领先的国际另类资产管理公司，今天宣布向Neuros Medical, Inc.（一家专注于通过神经调节技术缓解慢性截肢后疼痛并恢复生活质量的医疗技术公司）投入3500万美元的成长资本。

Neuros Medical's FDA-approved Altius Direct Electrical Nerve Stimulation System targets pain at its source by interrupting peripheral nerve signals responsible for phantom limb and residual limb pain. The system enables patients to activate therapy when needed, delivering targeted pain relief without relying on continuous medication.

Neuros Medical的FDA批准的Altius直接电神经刺激系统通过中断导致幻肢痛和残肢痛的外周神经信号，从源头上针对疼痛进行治疗。该系统允许患者在需要时启动治疗，提供针对性的疼痛缓解，而无需依赖持续用药。

With treatment options historically limited to opioid-based therapies, Altius offers a differentiated alternative for post-amputation pain..

历史上，治疗选择仅限于基于阿片类药物的疗法，而 Altius 为截肢后疼痛提供了与众不同的替代方案。

'Neuros Medical has reached an important inflection point as their technology moves into real-world adoption. We are proud to continue to support their team as they expand access to a differentiated therapy that addresses a significant need within the life sciences ecosystem,' said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital..

“Neuros Medical的技术进入现实世界应用，这标志着公司已经到达了一个重要的转折点。我们很自豪能够继续支持他们的团队，因为他们正在扩大一种差异化疗法的使用范围，这种疗法满足了生命科学生态系统中的重大需求，”Trinity Capital生命科学高级董事总经理Rob Lake表示。

This new capital will help Neuros Medical scale the commercialization of the Altius system and expand into new markets.

这笔新的资金将帮助Neuros Medical扩大Altius系统的商业化规模，并进军新市场。

'We appreciate the continued partnership from Trinity,' said David Veino, President & CEO of Neuros Medical. 'The Trinity team has been an important partner prior to us achieving FDA approval and will remain an important partner as we expand. This expansion of our debt facility provides important financial flexibility as Neuros enters the next phase of its mission to Relieve Pain and Restore Life for this underserved patient population.'.

“我们感谢Trinity的持续合作，”Neuros Medical总裁兼首席执行官David Veino表示。“Trinity团队在我们获得FDA批准之前一直是一个重要的合作伙伴，并且随着我们的扩展，他们将继续成为重要的合作伙伴。此次债务融资的扩大为Neuros进入下一阶段使命——缓解疼痛、恢复生活，服务这一未被充分满足的患者群体——提供了重要的财务灵活性。”

About Trinity Capital Inc.

关于三一资本公司

Trinity Capital Inc. (Nasdaq:

三一资本公司（纳斯达克：

TRIN

三角指标

) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences.

）是一家国际另类资产管理公司，通过进入私人信贷市场为投资者寻求提供稳定回报。Trinity Capital 在五个不同的借贷领域中寻找并构建对资本充足、成长导向型公司的投资：发起人融资、设备融资、科技贷款、基于资产的贷款和生命科学。

As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe.

作为寻求定制债务解决方案的创新公司的长期、可信赖的合作伙伴，自2008年成立以来（截至2025年12月31日），Trinity Capital已在463项投资中部署了超过55亿美元。Trinity Capital总部位于亚利桑那州凤凰城，其专业团队战略性地分布在美国和欧洲各地。

For more information on Trinity Capital, please visit .

有关三一资本的更多信息，请访问 。

trinitycapital.com

三一资本.com

and stay connected to the latest activity via

并通过以下方式保持与最新活动的连接

LinkedIn

领英

and

和

X

X

(@trincapital).

(@trincapital).

About Neuros Medical, Inc.

关于Neuros Medical公司

There are over two million patients in the U.S. living with limb loss and approximately 300,000 new lower limb amputations occurring every year. Post-amputation pain includes both phantom limb pain and residual limb pain, and impacts up to 80% of amputees, representing a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids.

美国有超过两百万名截肢患者，每年大约发生30万例新的下肢截肢。截肢后的疼痛包括幻肢痛和残肢痛，影响高达80%的截肢者，这代表了一个显著未满足的医疗需求，因为现有的治疗选择有限，主要依赖阿片类药物和加巴喷丁类药物。

Neuros Medical is a privately held company and the maker of the Altius® Direct Electrical Nerve Stimulation System, which is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. Our mission is to relieve pain and restore life for people suffering with post-amputation pain.

Neuros Medical是一家私人控股公司，也是Altius®直接电神经刺激系统的制造商，该系统已获得FDA批准，适用于成年截肢者慢性难治性幻肢和残肢下肢截肢后疼痛的辅助管理。我们的使命是为遭受截肢后疼痛的人们缓解疼痛，恢复生活。

We are a passionate team guided by our core values and committed to our patients and the healthcare professionals who care for them..

我们是一个由核心价值观引导的充满热情的团队，致力于为患者和照顾他们的医疗保健专业人员服务。

SOURCE Trinity Capital Inc.

来源：三一资本公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示